Skip to main content

The duration of Plasmodium falciparum infections


Plasmodium vivax and Plasmodium ovale are often considered the malaria parasites best adapted to long-term survival in the human host because of their latent exo-erythrocytic forms. The prevailing opinion until the middle of the last century was that the maximum duration of Plasmodium falciparum infections was less than two years. Case reports and series investigating blood donors following accidental malaria infection of blood transfusion recipients and other sporadic malaria cases in non-endemic countries have shown clearly that asymptomatic P. falciparum infections may persist for up to a decade or longer (maximum confirmed 13 years). Current policies in malaria-free countries of excluding blood donors who have lived in malarious areas are justified. Vigilance for longer than three years after declaring elimination in an area may be needed.


Plasmodium vivax and Plasmodium ovale are often considered the malaria parasites best adapted to long-term survival in the human host because of their latent exo-erythrocytic forms. Yet Plasmodium malariae, which has no latent forms, can persist asymptomatically in the blood for decades, and perhaps throughout the entire life of the host [1]. Many of these persistent asymptomatic P. malariae infections have been revealed by blood donation [2], with illness in the recipient (but not the donor). The maximum duration of asymptomatic infection is relevant both to transfusion risks and also in planning and evaluating malaria elimination.

Characterization of the natural history of untreated or partially treated Plasmodium falciparum malaria comes first from the early descriptions of neurosyphilis patients who were given malaria. Malariatherapy, the brainchild of the Viennese neuropsychiatrist Julius Wagner-Jauregg, was introduced as a treatment for neurosyphilis in the 1920s, and was widely used until supplanted by penicillin in the 1950s. The malariatherapy parasite of choice was generally P. vivax rather than the more dangerous P. falciparum, but all species were used. Detailed studies of syphilis patients infected with strains of P. falciparum reported durations of infection between 50 and 500 days depending on the infecting strain [3, 4].

The duration of P. falciparum infections was debated by malariologists during the first era of malaria eradication (in the 1950s) as it was a key consideration in the investigation of any sporadic cases in the post-elimination period. A review by Covell in 1960 presented the prevailing opinion that P. falciparum infections generally did not continue beyond one year although he noted nine cases where infection had recurred between one and two years after the primary infection, and he cited Ciuca’s review of 12,842 cases of experimental malaria from Romania showing a maximum persistence of P. falciparum infections of 27 months [57]. In 1964 Jacques Verdrager, a WHO malariologist, reviewed the literature again and added his own observations from the Malaria Eradication Project in Mauritius which suggested that P. falciparum could persist in humans for at least three years. One example was probable transfusion malaria from a donor who must have been parasitaemic for more than two years. Another was a presumed recrudescence of falciparum malaria in a young woman who had a documented episode of malaria three years previously, after which she had resided in an area considered free of malaria transmission [8]. Cohort studies in endemic areas have also proved informative. Between 1931 and 1934 in Puerto Rico, Earle followed a cohort of 71 schoolchildren prospectively with very frequent blood sampling for microscopy and found that some P. falciparum infections continued for up to 121 weeks [9].

A mathematical modelling approach has been used to estimate the duration of falciparum infections using repeated cross-sectional survey data from other cohorts, such as the subjects in the Garki project in the 1970s. Estimates for the total duration of infection across all age groups were long at 602 days (95% confidence interval (CI) 581–625) for Pare-Taveta (in Kenya/Tanzania), 734 days (95% CI 645–849) for West Papua, and 1,329 days (95% CI 1,193-1,499) for Garki in Nigeria [10]. Until molecular genotyping was introduced it was not possible to distinguish chronic single infections from multiple repeated infections in endemic areas, suggesting that the predicted longevity of blood stage infections based on microscopy data might be overestimated. The protracted duration of natural infections was demonstrated in Eastern Sudan where 16 of 43 individuals who had either had a malaria illness during the transmission season or were PCR positive for P. falciparum malaria at the end of the malaria season remained chronically infected throughout the dry season and the following rainy season with the same genotype [11].

In high-transmission areas asymptomatic parasitaemia is very common. The ability of individuals to control their parasitaemia at low levels without symptoms (premunition) results from the gradual acquisition of immunity following repeated or protracted exposure. In these areas uncomplicated and severe malaria are predominantly diseases of young children. Superinfection is usual with individuals harbouring multiple, genetically unrelated, parasite clones in a constantly changing equilibrium, often generating transmissible densities of gametocytes but remaining below the combined asexual parasite density that provokes illness [1214].

Hyperreactive malarial splenomegaly

Sometimes the host immune response to repeated malaria infection is excessive, manifest by the syndrome of hyper-reactive malarial splenomegaly (HMS); marked splenomegaly with hypersplenism and hypergammaglobulinaemia (in particular raised IgM). Plasmodium falciparum is usually responsible. Anti-malarial antibody titres are high but microscopy examination of blood smears is usually negative. Persistent or recurrent active malaria infection is confirmed by response (shrinkage of the spleen) to effective anti-malarial treatment (often in a prolonged course to prevent re-infection). Typical histopathological findings in the spleen are non-specific cellular hyperplasia and lymphocytic infiltration without malaria pigment. Two cases of symptomatic falciparum malaria occurring post splenectomy (performed for suspected lymphoma) were reported from France. Both were in immigrants who had not visited a malaria-endemic area for at least two years. Their diagnoses were changed to HMS retrospectively and indicate persistent active infection throughout this more than two years interval [15]. Similarly, a case report in Australia described a 28-years-old woman, born and brought up in Eritrea and Sudan, who developed falciparum malaria following splenectomy nine years after arriving in Australia. Histopathological findings in the spleen were compatible with HMS [16]. Examples of chronic falciparum infection, such as these from non-endemic countries, are very informative since the possibility of re-infection can be excluded with confidence. The richest source of information on persistent malaria comes from reports of malaria in recipients of blood transfusions or transplants in non-endemic areas.

Transfusion- and transplant-transmitted malaria

The first report of malaria as an accidental consequence of an artery to vein blood transfusion was described in 1910 by Woolsey [17]. The efficiency of blood transfusion in transmitting low density parasitaemias to naïve recipients was exploited by Fairley in his classic studies of the biology and chemotherapy of human malaria conducted in Cairns in the 1940s [18]. Fairley also observed protracted infections in some of his volunteers. A review of transfusion malaria published in 1974 summarized 2,001 cases of transfusion-transmitted malaria between 1911 and 1972, of which at least 88 were due to P. falciparum[19]. The details of most of these cases are not in the public domain. In those for whom information was available, the mean time between the transfusion and the onset of symptoms of malaria was 10.5 days (i.e., five asexual cycles) for the P. falciparum cases. Assuming a multiplication factor of approximately ten-fold per cycle and a pyrogenic threshold of 108 parasites in total in an adult, this suggests an inoculum of ~1,000 parasites in a blood bag or bottle of approximately 500 mL. Thus the likely donor density approximated an average of 2 parasites/mL, well below the pyrogenic (and microscopy detection threshold) density of ≥50,000/mL.


A search of Pubmed and Embase was performed for case reports of transfusion or transplant transmitted falciparum malaria or for cases of falciparum malaria presenting more than six months after leaving an endemic area. Cited references were used to identify other cases. Cases of transfusion-transmitted malaria from the USA were searched for in the annual MMWR malaria surveillance reports. Searches were also performed in websites of blood banks and the international haemovigilance network [20]. Reports of cases were excluded if the species was described as ‘tertian’ malaria without further clarification, if in languages other than English or French, or if the probable duration of the infection in the case or donor was six months or less.

Twenty-nine cases of transfusion and transplant-transmitted falciparum malaria are summarized in Table 1. The time interval from last possible exposure to malaria and the accidental transmission of the infection ranged from six months to 13 years, but was less than two years in half of the cases. However, this uses a very conservative definition of the last time the donor was in an endemic area as the time of acquisition, thus all the estimates here are minimum possible estimates and very likely underestimates of true durations of infection. Donors included immigrants from malaria-endemic countries and non-immune donors who had acquired their malaria abroad, e.g., soldiers. The time between the transfusion and the onset of symptoms varied between four days and four weeks. This suggests a variety of inocula and multiplication rates (Figures 1 and 2A).

Table 1 Transfusion or transplant transmitted falciparum malaria occurring at least six months after the donor’s last exposure risk
Figure 1
figure 1

Relationship between size of parasite inoculum and time to microscopy detection.

Figure 2
figure 2

Cases of transfusion or late-presenting clinical malaria showing minimum interval since last malaria exposure of donor or case. A Transfusion-transmitted falciparum malaria B Non-transfusion cases.

Table 2 and Figure 2 summarize 32 cases of falciparum malaria in individuals diagnosed between seven months and 15 years after leaving a malaria endemic area. Plasmodium falciparum gametocytaemia was reported in three of the cases. In one case, gametocytes were the only parasite stage seen on the blood film a month after a fever episode, suggesting the patient had self-cured the infection. Five cases reported having taken antimalarial drugs previously. In 13 cases the symptomatic episode coincided with pregnancy (seven women) or was associated with a co-morbidity, e.g., diagnosis of malignancy (one), diabetes mellitus (one), post head-injury (one), sickle-cell anaemia (one), HIV (two cases), which suggests a reduction in host immunity may have unmasked the latent infection.

Table 2 Non-transfusion cases of delayed presentation of falciparum malaria

Detection of occult malaria infections

The ability to detect asymptomatic carriers of malaria parasites depends on the sensitivity of the detection method used. Blood smear microscopy by experienced microscopists will detect parasite densities of ≥50/μL reliably. More recently, molecular methods have been employed to detect sub-patent parasitaemias. PCR is considerably more sensitive than microscopy or rapid diagnostic tests based on antigen detection but typically blood samples have been taken from finger-prick blood spots on filter paper, thus a volume of only ~5 μL has been amplified. This obviously misses densities which are below one parasite in 5 μL or 200 parasites/mL. In general, most PCR methods have limits of detection of ≥1,000 parasite/mL. Using larger blood volumes parasite densities down to ~20/mL can be detected, several orders of magnitude below the microscopy level of detection [60].

Malaria infection may also be assessed using serology, although interpretation is difficult. A variety of crude and more refined test antigens have been evaluated. Typically seroprevalence increases with age while the correlation with patent parasitaemia goes down [61, 62]. The usual duration of positive malaria antibody responses once an infection has been cleared with or without anti-malarials, in the absence of ongoing exposure, and the specificity of negative serology results to exclude active infection are both uncertain.

Longitudinal serological studies have been conducted in immigrants who have moved to countries that are malaria free. In a Spanish study IgG antibody levels against the erythrocytic antigens AMA-1 and MSP-142 (3D7 and FVO strains), EBA-175 and DBL-α, did not correlate with the time since migration [63]. Serology is used by a number of transfusion services for blood donor screening. Between 2005 and 2011, in the USA, 5,610 malaria-deferred donors were tested by EIA, including 5,412 travel deferrals. Overall, 88 (1.6%) of tests were EIA reactive on repeat testing, none of which were PCR positive [64]. In the transfusion-transmitted malaria cases summarized in Table 1, 11 donors had positive serology between ten months and 13 years after leaving an endemic area but were PCR or slide negative, suggesting that isolated positive serology may signify persistent low density parasitaemia below the detection threshold of conventional (i.e., low blood volume) PCR techniques which is approximately 1 parasite/μL. Given these uncertainties many blood transfusion services opt for a conservative policy of excluding donors who have lived in malaria-endemic areas.

Transmissibility of sub-microscopic Plasmodium falciparum infections

There is good evidence that chronic sub-patent infections are a source of onward mosquito transmission of malaria. In semi-immune individuals with persistent infections, gametocytaemia at densities below the limit of microscopy detection is often infectious [14]. In 1931 in South Africa, Swellengrebel estimated that crescent densities of only 1: 5,100 leucocytes were sufficient to infect anopheline mosquitoes and in 1945 Robertson recorded infections at thresholds below three crescents per 1,000 leucocytes in Anopheles gambiae in West Africa [5]. Ciuca et al. studied the infectivity of long-term asymptomatic P. falciparum malaria to laboratory-bred Anopheles atroparvus following experimentally induced infections in ten individuals [6]. They observed infectivity rates of 0.7-7% even when no gametocytes were seen on microscopy examination of three thick films. Transmission was confirmed up to the 175th day after infection.


These reports show unequivocally that P. falciparum can survive for extended periods in the human host. The previously quoted maximum duration of two years should be revised; 13 years is the maximum confirmed duration reported to date. The transfusion malaria cases suggest the parasite continues its erythrocytic life cycle at very low densities, kept in check by the host’s immune response. This is a common pattern for malaria parasites in all animals, and is the most likely explanation for persistence of both P. falciparum and P. malariae in man. There is no evidence for protracted dormancy or an exo-erythrocytic parasite stage of these parasites, although it is possible that the entire life cycle could take place in the vascular spaces in the placenta or spleen. Incomplete antimalarial drug treatment may have a modulatory effect on the infection early on. As well as the poorly understood host’s response to the parasite, P. falciparum possesses sophisticated immune evasion mechanisms, notably the differential serial expression of var genes encoding for Pf EMP1, the major surface antigen of the blood stage [65]. How P. falciparum parasites survive for prolonged periods in the human host without exhausting their repertoire of antigenic variation is unclear. The appearance of symptoms years after infection may reflect waning of host immunity. The late recrudescing infections presented in Table 2 were associated with concomitant conditions, which may have led to immunosuppression in several cases, e.g., diabetes mellitus, malignancy, and pregnancy.

It is not possible to estimate how common chronic infection with P. falciparum might be. The World Malaria Report estimated that in 2012 there were between 135 and 287 million malaria cases of which 91% were caused by P. falciparum[66]. Even if only a tiny proportion of untreated or partially treated infections become indolent, this represents a huge potential reservoir of sustained transmission.

Approximately 107 million units of blood donations are collected globally every year [67]. Very few blood transfusion services perform routine malaria antibody testing, with most non-endemic countries relying on deferral of donors considered to be at risk. This appears to be very effective in preventing the vast majority of cases of transfusion-transmitted malaria [68]. It is also possible that some transfusion-transmitted parasites do not cause disease. A large proportion of the transfusion-recipients presented in Table 1 were older, with co-morbidities such as malignancy, diabetes, end-stage renal failure, and sickle-cell anaemia and thus may have been more susceptible to malaria following inoculation of very low numbers of parasites than immunocompetent recipients. The requirement for blood transfusion indicates anaemia and therefore illness. Furthermore, blood transfusion itself is associated with immunosuppression [69]. The incidence of transfusion-transmitted malaria in endemic countries is probably far higher than realised since screening by microscopy only is usually the method used to select donors and antimalarial drugs are not added to blood donations. Transfusion malaria could become an important source of malaria within countries where there is incomplete elimination.

These observations on the longevity of falciparum infections and the sub-microscopic parasite burden are relevant to immigrants and refugees who have left malarious areas. In a parasite prevalence study of 195 African refugees in Italy in 2007, 62 patients tested positive for malaria using molecular detection methods, of whom 13 were gametocytaemic. Microscopy confirmed the positive results in 14 of the 62 cases, of which 13 were P. falciparum[70]. The reported prevalence of asymptomatic malaria in refugees screened post-arrival ranges from 2.4 to 31.8%, depending on the population and the method of diagnosis. Where malaria vectors are present these people may act as a source of transmission. The possibility that asymptomatic infections with artemisinin-resistant falciparum malaria could be imported from Southeast Asia to Africa is a current concern.

In countries targeting malaria elimination, achieving this aim is likely to take longer if the sub-microscopic parasites are not eliminated. Improved high-throughput and low-cost methods are needed to detect these individuals harbouring low parasite densities. Conventional PCR methods still miss infections with densities below 1/uL. Serology has been proposed as a useful tool to detect changes in malaria transmission in settings where transmission is in decline and appears to be a sensitive method for the detection of malaria infection but its specificity is unclear, as is the usual duration of detectable antibodies once an infection has cleared. There is a need to investigate the role of serology in defining asymptomatic carriage, certainly in lower transmission and pre-elimination countries.

Plasmodium falciparum can persist in the human host for longer than thought previously. Current policies in malaria-free countries of excluding blood donors who have lived in malarious areas are justified. Vigilance for longer than three years after declaring elimination in an area may be needed.


  1. 1.

    Collins WE, Jeffery GM: Plasmodium malariae: parasite and disease. Clin Microbiol Rev. 2007, 20: 579-592. 10.1128/CMR.00027-07.

    PubMed Central  Article  PubMed  Google Scholar 

  2. 2.

    Brouwer EE, van Hellemond JJ, van Genderen PJ, Slot E, van Lieshout L, Visser LG, Wismans PJ: A case report of transfusion-transmitted Plasmodium malariae from an asymptomatic non-immune traveller. Malar J. 2013, 12: 439-10.1186/1475-2875-12-439.

    PubMed Central  Article  PubMed  Google Scholar 

  3. 3.

    Jeffery GM, Eyles DE: The duration in the human host of infections with a Panama strain of Plasmodium falciparum. Am J Trop Med Hyg. 1954, 3: 219-224.

    CAS  PubMed  Google Scholar 

  4. 4.

    Eyles DE, Young MD: The duration of untreated or inadequately treated Plasmodium falciparum infections in the human host. J Natl Malar Soc. 1951, 10: 327-336.

    CAS  PubMed  Google Scholar 

  5. 5.

    Covell G: Relationship between malarial parasitaemia and symptoms of the disease: a review of the literature. Bull World Health Organ. 1960, 22: 605-619.

    PubMed Central  CAS  PubMed  Google Scholar 

  6. 6.

    Ciuca M, Lupasco G, Ballif-Negulici E, Constantinesco P, Cristesco A, Sandesco I: Experimental research on the infectivity for A. atroparvus of P. vivax or P. falciparum asymptomatic parasitaemias in relation to acquired immunity in countries where malaria is endemic. 1963, Geneva: World Health Organization, WHO_Mal_378.pdf

    Google Scholar 

  7. 7.

    Bruce-Chwatt LJ: Malaria research and eradication in the USSR. A review of Soviet achievements in the field of malariology. Bull World Health Organ. 1959, 21: 737-772.

    PubMed Central  CAS  PubMed  Google Scholar 

  8. 8.

    Verdrager J: Observations on the longevity of Plasmodium falciparum: with special reference to findings in Mauritius. Bull World Health Organ. 1964, 31: 747-751.

    PubMed Central  CAS  PubMed  Google Scholar 

  9. 9.

    Earle WC: The Course of Naturally Acquired Malaria. 1962, Geneva: World Health Organization, WHO_Mal_333.pdf

    Google Scholar 

  10. 10.

    Sama W, Killeen G, Smith T: Estimating the duration of Plasmodium falciparum infection from trials of indoor residual spraying. Am J Trop Med Hyg. 2004, 70: 625-634.

    PubMed  Google Scholar 

  11. 11.

    Hamad AA, El Hassan IM, El Khalifa AA, Ahmed GI, Abdelrahim SA, Theander TG, Arnot DE: Chronic Plasmodium falciparum infections in an area of low intensity malaria transmission in the Sudan. Parasitology. 2000, 120: 447-456. 10.1017/S0031182099005818.

    Article  PubMed  Google Scholar 

  12. 12.

    al-Yaman F, Genton B, Reeder JC, Anders RF, Smith T, Alpers MP: Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area: a prospective community study. Trans R Soc Trop Med Hyg. 1997, 91: 602-605. 10.1016/S0035-9203(97)90046-8.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Bruce MC, Galinski MR, Barnwell JW, Donnelly CA, Walmsley M, Alpers MP, Walliker D, Day KP: Genetic diversity and dynamics of Plasmodium falciparum and P. vivax populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea. Parasitology. 2000, 121: 257-272. 10.1017/S0031182099006356.

    Article  PubMed  Google Scholar 

  14. 14.

    Bousema T, Drakeley C: Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011, 24: 377-410. 10.1128/CMR.00051-10.

    PubMed Central  Article  PubMed  Google Scholar 

  15. 15.

    Bidegain F, Berry A, Alvarez M, Verhille O, Huguet F, Brousset P, Pris J, Marchou B, Magnaval JF: Acute Plasmodium falciparum malaria following splenectomy for suspected lymphoma in 2 patients. Clin Infect Dis. 2005, 40: e97-100. 10.1086/430061.

    Article  PubMed  Google Scholar 

  16. 16.

    Howden BP, Vaddadi G, Manitta J, Grayson ML: Chronic falciparum malaria causing massive splenomegaly 9 years after leaving an endemic area. Med J Aust. 2005, 182: 3-

    Google Scholar 

  17. 17.

    Woolsey G: Transfusion for pernicious anemia: Two cases. Ann Surg. 1911, 53: 3-

    Google Scholar 

  18. 18.

    Fairley NH: Sidelights on malaria in man obtained by subinoculation experiments. Trans R Soc Trop Med Hyg. 1947, 40: 621-676. 10.1016/0035-9203(47)90025-4.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Bruce-Chwatt LJ: Transfusion malaria. Bull World Health Organ. 1974, 50: 337-346.

    PubMed Central  CAS  PubMed  Google Scholar 

  20. 20.

    Website of the International Haemovigilance network. []

  21. 21.

    Black RH: Investigation of blood donors in accidental transfusion malaria-Plasmodium vivax, falciparum and malariae infections. Med J Aust. 1960, 2: 446-449.

    Google Scholar 

  22. 22.

    Chojnacki RE, Brazinsky JH, Barrett O: Transfusion-introduced falciparum malaria. N Engl J Med. 1968, 279: 984-985. 10.1056/NEJM196810312791808.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Fisher GU, Schultz MG: Unusual host-parasite relationship in blood-donors responsible for transfusion-induced falciparum malaria. Lancet. 1969, 2: 716-718.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Brooks MH, Barry KG: Fatal transfusion malaria. Blood. 1969, 34: 806-810.

    CAS  PubMed  Google Scholar 

  25. 25.

    Dike A, Draper CC: A case of transfusion malaria due to Plasmodium falciparum with antibody studies of the donors. Trans R Soc Trop Med Hyg. 1970, 64 (1): 1-PubMed PMID: 4909856

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Seligman SJ, Choa MS: Transfusion-induced falciparum malaria. JAMA. 1971, 217: 479-10.1001/jama.1971.03190040071030.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Duizabo P, Romano P, Usdin JP, Barbizet J: [Transfusion induced malaria with serious mental disturbance. Report of a case](in French). Concours Med. 1974, 96: 3-

    Google Scholar 

  28. 28.

    Besson P, Robert JF, Reviron J, Richard-Lenoble D, Gentilini M: A propos de deux observations de paludisme transfusionnel. Essai de prevention associant un test d'immunofluorescence indirecte aux criteres de selection clinique. Revue Francaise de Transfusion et Immuno-hematologie. 1976, XIX: 4-

    Google Scholar 

  29. 29.

    Saleun JP, Baret M, Dauriac J: Resultats d'une enquire sur le paludisme post-transfusionnel en France entre 1960 et 1974. Revue Francaise de Transfusion et Immuno-hematologie. 1976, XIX: 11-

    Google Scholar 

  30. 30.

    Duperval R, Longpre B, Madarnas P: Unexplained falciparum malaria in a patient with chronic lymphocytic leukemia. Can Med Assoc J. 1979, 121: 1585-1588.

    PubMed Central  CAS  PubMed  Google Scholar 

  31. 31.

    Babinet J, Gay F, Bustos D, Dubarry M, Jaulmes D, Nguyen L, Gentilini M: Transmission of Plasmodium falciparum by heart transplant. BMJ. 1991, 303: 1515-1516. 10.1136/bmj.303.6816.1515.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  32. 32.

    Yarrish RL, Janas JS, Nosanchuk JS, Steigbigel RT, Nusbacher J: Transfusion malaria: treatment with exchange transfusion after delayed diagnosis. Arch Intern Med. 1982, 142: 187-188. 10.1001/archinte.1982.00340140189034.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Stickland JF, Roberts AN, Williams V: Transfusion-induced malaria in Victoria. Med J Aust. 1992, 157: 499-500.

    CAS  PubMed  Google Scholar 

  34. 34.

    Slinger R, Giulivi A, Bodie-Collins M, Hindieh F, John RS, Sher G, Goldman M, Ricketts M, Kain KC: Transfusion-transmitted malaria in Canada. Can Med Assoc J. 2001, 164: 377-379.

    CAS  Google Scholar 

  35. 35.

    Frey-Wettstein A, Maier M, Markwalder K, Münch U: A case of transfusion transmitted malaria in Switzerland. Swiss Med Wkly. 2001, 131: 320-

    CAS  PubMed  Google Scholar 

  36. 36.

    Eliades MJ, Shah S, Nguyen-Dinh P, Newman RD, Barber AM, Nguyen-Dinh P, Roberts JM, Mali S, Parise ME, Barber AM, Steketee R: Malaria surveillance–United States, 2003. MMWR Surveill Summ. 2005, 54: 25-40.

    PubMed  Google Scholar 

  37. 37.

    Bruneel F, Thellier M, Eloy O, Mazier D, Boulard G, Danis M, Bedos JP: Transfusion-transmitted malaria. Intensive Care Med. 2004, 30: 1851-1852.

    Article  PubMed  Google Scholar 

  38. 38.

    Kitchen AD, Barbara JA, Hewitt PE: Documented cases of post-transfusion malaria occurring in England: a review in relation to current and proposed donor-selection guidelines. Vox Sang. 2005, 89: 77-80. 10.1111/j.1423-0410.2005.00661.x.

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Centers for Disease C, Prevention: Travel-associated Dengue surveillance - United States, 2006–2008. MMWR Morb Mortal Wkly Rep. 2010, 59: 715-719.

    Google Scholar 

  40. 40.

    Mali S, Tan KR, Arguin PM: Division of Parasitic Diseases, Malaria CfGH, Centers for Disease Control and Prevention: Malaria surveillance–United States, 2009. MMWR Surveill Summ. 2011, 60: 1-15.

    PubMed  Google Scholar 

  41. 41.

    Mali S, Kachur SP, Arguin PM: Division of Parasitic Diseases, Malaria CfGH, Centers for Disease Control and Prevention: Malaria surveillance–United States, 2010. MMWR Surveill Summ. 2012, 61: 1-17.

    PubMed  Google Scholar 

  42. 42.

    Lefavour GS, Pierce JC, Frame JD: Renal transplant-associated malaria. JAMA. 1980, 244: 1820-1821. 10.1001/jama.1980.03310160036021.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Nagley L: Probable relapse of malignant tertian malaria after thirteen years. Lancet. 1945, 2: 773-

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Walters J: Quiescent malarial parasites. BMJ. 1960, i: 1206-1207.

    Article  Google Scholar 

  45. 45.

    Russell PF, West LS, Manwell RD, Macdonald G: Practical Malariology. 1963, London: Oxford University Press, 2

    Google Scholar 

  46. 46.

    Revel MP, Datry A, Saint Raimond A, Lenoir G, Danis M, Gentilini M: Plasmodium falciparum malaria after three years in a non-endemic area. Trans R Soc Trop Med Hyg. 1988, 82: 832-10.1016/0035-9203(88)90008-9.

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Kyrönseppä H, Tiula E, Repo H, Lähdevirta J: Diagnosis of falciparum malaria delayed by long incubation period and misleading presenting symptoms: life-saving role of manual leucocyte differential count. Scand J Infect Dis. 1989, 21: 117-118. 10.3109/00365548909035690.

    Article  PubMed  Google Scholar 

  48. 48.

    Krajden SP, Panisko DM, Tobe B, Yang J, Keystone JS: Prolonged infection with Plasmodium falciparum in a semi-immune patient. Trans R Soc Trop Med Hyg. 1991, 85: 731-732. 10.1016/0035-9203(91)90434-Z.

    CAS  Article  PubMed  Google Scholar 

  49. 49.

    Shah S, Filler S, Causer LM, Rowe AK, Bloland PB, Barber AM, Roberts JM, Desai MR, Parise ME, Steketee RW: Malaria surveillance–United States, 2002. MMWR Surveill Summ. 2004, 53: 21-34.

    PubMed  Google Scholar 

  50. 50.

    Giobbia M, Tonon E, Zanatta A, Cesaris L, Vaglia A, Bisoffi Z: Late recrudescence of Plasmodium falciparum malaria in a pregnant woman: a case report. Int J Infect Dis. 2005, 9: 234-235. 10.1016/j.ijid.2004.08.002.

    Article  PubMed  Google Scholar 

  51. 51.

    Lesko CR, Arguin PM, Newman RD: Congenital malaria in the United States: a review of cases from 1966 to 2005. Arch Pediatr Adolesc Med. 2007, 161: 1062-1067. 10.1001/archpedi.161.11.1062.

    Article  PubMed  Google Scholar 

  52. 52.

    Greenwood T, Vikerfors T, Sjoberg M, Skeppner G, Farnert A: Febrile Plasmodium falciparum malaria 4 years after exposure in a man with sickle cell disease. Clin Infect Dis. 2008, 47: e39-41. 10.1086/590250.

    Article  PubMed  Google Scholar 

  53. 53.

    D'Ortenzio E, Godineau N, Fontanet A, Houze S, Bouchaud O, Matheron S, Le Bras J: Prolonged Plasmodium falciparum infection in immigrants, Paris. Emerg Infect Dis. 2008, 14: 324-326.

    Google Scholar 

  54. 54.

    Theunissen C, Janssens P, Demulder A, Nouboussie D, Van-Esbroeck M, Van-Gompel A, Van-Denende J: Falciparum malaria in patient 9 years after leaving malaria-endemic area. Emerg Infect Dis. 2009, 15: 115-116. 10.3201/eid1501.080909.

    PubMed Central  Article  PubMed  Google Scholar 

  55. 55.

    Foca E, Zulli R, Buelli F, De Vecchi M, Regazzoli A, Castelli F: P. falciparum malaria recrudescence in a cancer patient. Infez Med. 2009, 17: 33-34.

    CAS  PubMed  Google Scholar 

  56. 56.

    Szmitko PE, Kohn ML, Simor AE: Plasmodium falciparum malaria occurring 8 years after leaving an endemic area. Diagn Microbiol Infect Dis. 2009, 63: 105-107. 10.1016/j.diagmicrobio.2008.08.017.

    Article  PubMed  Google Scholar 

  57. 57.

    Cullen KA, Arguin PM: Division of Parasitic Diseases, Malaria CfGH Centers for Disease Control and Prevention: Malaria surveillance–United States, 2011. MMWR Surveill Summ. 2013, 62: 1-17.

    PubMed  Google Scholar 

  58. 58.

    Monge-Maillo BN, Norman F, Pérez-Molina JA, Díaz-Menéndez M, Rubio JM, López-Vélez R: Plasmodium falciparum in asymptomatic immigrants from sub-Saharan Africa, Spain. Emerg Infect Dis. 2012, 18: 356-357. 10.3201/eid1801.111283.

    PubMed Central  Article  PubMed  Google Scholar 

  59. 59.

    Berrevoets MA, Sprong T, Meis JF, Dofferhoff AS: Plasmodium falciparum malaria recrudescence occurring 2.5 years after leaving an endemic country. Neth J Med. 2013, 71: 426-428.

    CAS  PubMed  Google Scholar 

  60. 60.

    Imwong M, Hanchana S, Malleret B, Renia L, Day NP, Dondorp A, Nosten F, Snounou G, White NJ: High throughput ultra-sensitive molecular techniques to quantify low density malaria parasitaemias. J Clin Microbiol. 2014, 52: 3303-3309. 10.1128/JCM.01057-14.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  61. 61.

    Satoguina J, Walther B, Drakeley C, Nwakanma D, Oriero EC, Correa S, Corran P, Conway DJ, Walther M: Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau. Malar J. 2009, 8: 274-10.1186/1475-2875-8-274.

    PubMed Central  Article  PubMed  Google Scholar 

  62. 62.

    Hsiang MS, Hwang J, Kunene S, Drakeley C, Kandula D, Novotny J, Parizo J, Jensen T, Tong M, Kemere J, Dlamini S, Moonen B, Angov E, Dutta S, Ockenhouse C, Dorsey G, Greenhouse B: Surveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serology. PLoS One. 2012, 7: e29550-10.1371/journal.pone.0029550.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  63. 63.

    Moncunill G, Mayor A, Bardaji A, Puyol L, Nhabomba A, Barrios D, Aguilar R, Pinazo MJ, Almirall M, Soler C, Dlamini S, Moonen B, Angov E, Dutta S, Ockenhouse C, Dorsey G, Greenhouse B: Cytokine profiling in immigrants with clinical malaria after extended periods of interrupted exposure to Plasmodium falciparum. PLoS One. 2013, 8: e73360-10.1371/journal.pone.0073360.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  64. 64.

    Nguyen ML, Goff T, Gibble J, Steele WR, Leiby DA: Analyzing actual risk in malaria-deferred donors through selective serologic testing. Transfusion. 2013, 53: 1736-1743. 10.1111/trf.12004.

    CAS  Article  PubMed  Google Scholar 

  65. 65.

    Barry AE, Leliwa-Sytek A, Tavul L, Imrie H, Migot-Nabias F, Brown SM, McVean GA, Day KP: Population genomics of the immune evasion (var) genes of Plasmodium falciparum. PLoS Pathog. 2007, 3: e34-10.1371/journal.ppat.0030034.

    PubMed Central  Article  PubMed  Google Scholar 

  66. 66.

    WHO: World Malaria Report 2013. 2013, Geneva: World Health Organization

    Google Scholar 

  67. 67.

    World Health Organisation: 10 facts on blood transfusion.]

  68. 68.

    Reesink HW, Panzer S, Wendel S, Levi JE, Ullum H, Ekblom-Kullberg S, Seifried E, Schmidt M, Shinar E, Prati D, Berzuini A, Ghosh S, Flesland Ø, Jeansson S, Zhiburt E, Piron M, Sauleda S, Ekermo B, Eglin R, Kitchen A, Dodd RY, Leiby DA, Katz LM, Kleinman S: The use of malaria antibody tests in the prevention of transfusion-transmitted malaria. Vox Sang. 2010, 98: 468-478. 10.1111/j.1423-0410.2009.01301.x.

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Vamvakas EC, Blajchman MA: Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007, 21: 327-348. 10.1016/j.blre.2007.07.003.

    Article  PubMed  Google Scholar 

  70. 70.

    Marangi M, Di Tullio R, Mens PF, Martinelli D, Fazio V, Angarano G, Schallig HD, Giangaspero A, Scotto G: Prevalence of Plasmodium spp. in malaria asymptomatic African migrants assessed by nucleic acid sequence based amplification. Malar J. 2009, 8: 12-10.1186/1475-2875-8-12.

    PubMed Central  Article  PubMed  Google Scholar 

Download references


We would like to thank Dr Alan Kitchen for providing additional information on transfusion related malaria.

Author information



Corresponding author

Correspondence to Elizabeth A Ashley.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

NJW had the idea for the review. EAA reviewed the literature. Both authors drafted the manuscript. Both authors read and approved the final manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ashley, E.A., White, N.J. The duration of Plasmodium falciparum infections. Malar J 13, 500 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Plasmodium falciparum
  • Transfusion malaria
  • Longevity
  • Asymptomatic
  • Sub-microscopic